TY - JOUR T1 - Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario JO - Anais Brasileiros de Dermatologia T2 - AU - Sanches,José Antonio AU - Cury-Martins,Jade AU - Abreu,Rodrigo Martins AU - Miyashiro,Denis AU - Pereira,Juliana SN - 03650596 M3 - 10.1016/j.abd.2020.12.007 DO - 10.1016/j.abd.2020.12.007 UR - http://www.anaisdedermatologia.org.br/en-mycosis-fungoides-sezary-syndrome-focus-articulo-S0365059621001161 AB - Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups: skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sézary syndrome. ER -